Cite
HARVARD Citation
Peluso, M. et al. (2020). The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. Journal for immunotherapy of cancer. 8 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Peluso, M. et al. (2020). The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. Journal for immunotherapy of cancer. 8 (1), p. . [Online].